Recency
Utkarsh Amitabh is a founder, author and Ph.D. candidate who spends 3.5 hours a day, on average, training AI models for tech startup micro1.
Viewed by You are the first to view
American Airlines will no longer award AAdvantage miles or Loyalty Points on basic economy fares.
Interested?
Viewed by You are the first to view
The F-150 Lightning economics did not add up but also reflected industry-wide miscalculation of US EV uptake
Viewed by You are the first to view
The fast-fashion giant welcomed the judgement and said its priority remains protecting French consumers.
Viewed by You are the first to view
Members of the carrier's AAdvantage loyalty program no longer earn miles or status points when purchasing a basic ticket.
Interested?
Viewed by You are the first to view
We've all seen people jumping over the turnstiles to avoid paying for their train rides, but it's soon going to be more difficult for fare beaters to do that.
Interested?
Viewed by You are the first to view
Consumer sentiment sits near record low at the end of 2025, but the news isn’t all bad
Viewed by You are the first to view
By purchasing Graphite, Cursor, currently valued at $29 billion, gains more code review and debugging capabilities.
Interested?
Viewed by You are the first to view
The Federal Reserve Board on Friday requested public input on a "payment account," which eligible financial institutions could use for the limited purpose of c
Interested?
Viewed by You are the first to view
High prices, high interest rates and cooling rents: These days tenancy (versus owning a home) in California has its perks.
Interested?
Viewed by You are the first to view
Nearly 100 bars and restaurants shuttered, many of them mid-priced places.
Viewed by You are the first to view
Viewed by You are the first to view
Don't get swindled while buying those last-minute gifts. Amy Nofziger, a fraud specialist with AARP, shares top schemes she's been seeing this season — and tips on how to protect yourself.
Viewed by You are the first to view
Grassroots campaigns against data centers are growing and costing the industry billions in canceled and delayed projects.
Interested?
Viewed by You are the first to view
California's minimum wage is adjusted every year for inflation and an increase will take effect on Jan. 1, 2026. Some cities have a higher wage floor.
Interested?
Viewed by You are the first to view
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximatel…
Viewed by You are the first to view
$7 trillion of options and futures are set to expire as indexes and portfolios are rebalanced.
Viewed by You are the first to view
Goldman Sachs Research projects that global GDP will outperform consensus economist estimates in 2026. The US is expected to benefit from factors such as tax cuts, while China contends with strong exports but sluggish domestic demand.
Viewed by You are the first to view
Grid operator PJM was unable to secure enough promised power to reach its reliability goal during an auction this week.
Viewed by You are the first to view
The retailer says it plans to claw back bonuses awarded to executives at its North America business as a result of the mistakes.
Viewed by You are the first to view
Connected toys like tablets, smartwatches, and robots now store everything from a kid's photos to their location.
Viewed by You are the first to view
Central bank dashes hopes of strong recovery from debt-funded spending spree
Viewed by You are the first to view
The chip industry in China is hustling to overcome a Western tech choke hold, even as President Trump appears poised to loosen U.S. chip restrictions.
Viewed by You are the first to view
Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority review voucher program for drug companies.
Viewed by You are the first to view
The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.
Viewed by You are the first to view